Abstract
MicroRNAs are poised to radically change the way we care for patients with germ cell tumors (GCTs) across all disease states, from diagnosis to managing chemorefractory disease. miR-371a-3p is a promising candidate biomarker that may precisely individualize GCT treatment paradigms.
Original language | English (US) |
---|---|
Pages (from-to) | 541-542 |
Number of pages | 2 |
Journal | European Urology |
Volume | 76 |
Issue number | 5 |
DOIs | |
State | Published - Nov 2019 |
Externally published | Yes |
ASJC Scopus subject areas
- Urology